Integra LifeSciences Holdings Corporation, the Forrestal Center-based global medical technology company, has announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development across the company.
The company also announced the appointments of Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer.
As CTO, Elavia will work to align R&D priorities with the company’s strategic imperatives, accelerate the impact and speed of product development programs, and strengthen the company’s innovation pipeline through organic and partnership efforts. He will also help identify emerging trends and technologies that reinforce the company’s market leadership and provide opportunities for growth.
Elavia brings more than 20 years of experience in new product development spanning imaging and navigation, minimally invasive surgery, regenerative medicine, diabetes care, and autoimmune diseases, with senior R&D leadership roles at Becton Dickinson, Eli Lilly, Medtronic, and Johnson & Johnson. Most recently, he served as vice president of R&D for Becton Dickinson’s Medical Delivery Solutions business, where he led the development of an R&D roadmap to drive growth in high-value markets and advanced connected care innovation initiatives.
Michael Hutchinson will lead the company’s global legal, compliance, and environmental, social and governance (ESG) functions and serve as the principal legal advisor to the executive leadership team and board of directors. He is a seasoned attorney and business leader with more than 20 years of experience spanning complex litigation, corporate governance, risk management, ESG matters, and more than 80 acquisitions and integrations. Prior to joining Integra, Hutchinson served as senior vice president and chief legal officer at LivaNova, with prior chief legal officer roles at Stryker and Varian Medical Systems.
Kerri DiPietro will lead Integra’s global quality organization, driving the execution of the company’s enterprise-wide Compliance Master Plan and overseeing the strengthening and harmonization of the global quality management system. Her responsibilities will encompass all global quality activities, including design assurance, post-market surveillance, supplier quality, complaint handling, and validation. DiPietro joins Integra from Haemonetics, where she served as senior vice president of global quality and compliance, and led improvements in product quality, regulatory compliance, and global quality system integration. Prior to Haemonetics, she was at Boston Scientific, where she held roles in R&D, operations and quality.
“Creating a dedicated chief technology officer role is a decisive step in how we are building Integra for the future,” said Mojdeh Poul, president and CEO of Integra LifeSciences. “Innovation is a core strategic imperative for us, and Teshtar brings deep experience translating emerging technologies into impactful solutions. Together with the additions of Kerri and Mike, these appointments reflect our commitment to assembling a seasoned, highly respected leadership team that can deliver our transformation and drive long-term value.”
Learn more at www.integralife.com.
